|
Alan G. Harris has 20 years of experience working in clinical drug development in the pharmaceutical industry. He was recently Corporate Head of the Worldwide Medical Endocrine Care group at Pfizer Inc, New York. Before that, while at Schering-Plough, he served in a number of capacities in Medical Affairs and recently as Vice President Global Healthcare Research & Outcomes. During his tenure at Sandoz Pharmaceuticals (Novartis) he was the Clinical Project Leader for the development of Sandostatin ®.
Dr. Harris is currently Adjunct Professor of Medicine at NYU Medical School and Visiting Professor of Medicine in the Department of Endocrinology at Liège University Medical School, Belgium. Dr. Harris received his M.D. from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France and his Ph.D. in Endocrinology from Erasmus University, Rotterdam, The Netherlands. He was a practicing internist for seven years and an attending physician in the department of Gastroenterology at Nice University Hospital, France. He was Associate Professor of Medicine and, Director, Division of Clinical Pharmacology, Department of Medicine and Medical Director of the Department of Technology Development and Transfer and Clinical Trials at Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles. Dr. Harris is a Fellow of the American College of Physicians, the Royal College of Physicians (UK) and the Royal Society of Medicine. He has authored over 200 publications including 100 peer reviewed scientific papers. He is currently a Trustee of the Hospital for Joint Diseases-New York University Medical Center. | 